Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling

Phuong Doan1,2,3, Aliyu Musa1,2,3, Akshaya Murugesan1,2,4

  • 1Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 553, 33101 Tampere, Finland.

Cells
|March 14, 2020
PubMed

Insights

The synthetic phenol THTMP effectively targets cancer stem cells (CSCs) in glioblastoma, inhibiting proliferation and inducing apoptosis. THTMP shows promise as a therapeutic agent, outperforming temozolomide in certain resistance variants.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Stem Cell Research

Background:

  • Cancer stem cells (CSCs) drive tumor growth and therapeutic resistance.
  • Targeting CSC stemness is a critical therapeutic strategy.
  • Glioblastoma multiforme (GBM) presents significant treatment challenges due to its heterogeneous cell populations.

Purpose of the Study:

  • To evaluate the therapeutic potential of the synthetic phenol THTMP against GBM.
  • To elucidate the mechanisms by which THTMP affects CSCs and non-stem cancer cells (NSCCs).
  • To assess THTMP's efficacy compared to temozolomide (TMZ) in GBM models.

Main Methods:

  • Utilized CD133+ GBM stem cells (GSCs) and CD133- NSCCs from LN229 and SNB19 cell lines.
  • Performed cell cycle analysis, apoptosis assays, and transcriptome analysis.
  • Investigated the impact of THTMP on key signaling pathways including p53, EGFR, Wnt, Notch, and Hedgehog.

Main Results:

  • THTMP inhibited both GSCs and NSCCs in a time-dependent manner, with notable efficacy against resistant variants compared to TMZ.
  • THTMP induced G1/S and G2/M cell cycle arrest and promoted ROS-mediated apoptosis in CSCs.
  • Gene expression profiling revealed THTMP's inhibition of the p53 pathway, leading to DNA damage and cell cycle arrest, and its modulation of EGFR and CSC-related pathways.

Conclusions:

  • THTMP demonstrates significant anti-cancer effects on GBM by targeting CSC stemness and proliferation.
  • THTMP disrupts critical CSC signaling pathways (Wnt, Notch, Hedgehog) and modulates EGFR signaling.
  • THTMP represents a promising therapeutic candidate for GBM, particularly against resistant cell populations.